Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (66.7%)
Phase 41 (33.3%)

Trials by Status

terminated133%
unknown133%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_4

Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

NCT04819360
unknownphase_2

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

NCT06034288
not_yet_recruitingphase_2

Investigating Temporalis and Masseter Botox Injection Before Orthognathic Surgery to Improve Postoperative Pain

NCT04794504

Clinical Trials (3)

Showing 3 of 3 trials
NCT04819360Phase 4

Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

Terminated
NCT06034288Phase 2

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

Unknown
NCT04794504Phase 2

Investigating Temporalis and Masseter Botox Injection Before Orthognathic Surgery to Improve Postoperative Pain

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3